What patent covers Seebri (glycopyrronium) and who owns it?
The key patents for Seebri are those covering glycopyrronium (a long-acting muscarinic antagonist) as a product and its use in treating respiratory disease. Patent ownership is tied to the manufacturer and product holder for the Seebri brand in each country, and the exact patent numbers you need depend on the jurisdiction you’re checking (for example, US vs. EU vs. UK).
When do Seebri patents expire (and why different dates show up)?
Seebri’s “patent expiry” date can differ from one another depending on whether you’re looking at:
- the end of the underlying patent term,
- any patent term extensions (common in some jurisdictions),
- and regulatory exclusivities (which can add extra time even after a patent ends).
Because these elements are country-specific, the only reliable way to get the exact expiry timeline is to look up the patents tied to the Seebri marketing authorization in the specific country.
Can generic or biosimilar Seebri versions launch before patent expiry?
If you mean “generic” Seebri (small-molecule inhaled medicine), generics can sometimes be approved or launched once the relevant exclusivities and blocking patents expire. In markets with patent-linkage systems, approvals may be delayed by active patents, even if the underlying molecule is otherwise off-patent in another region.
Are there patent disputes involving Seebri?
Patent litigation and settlement agreements can affect when a generic product actually enters the market, even if an expiry date is already near or even if some patents expire earlier than others. The presence and outcome of disputes are also jurisdiction-dependent.
Which country should you check for the Seebri patent you mean?
To give you a precise answer (patent number + owner + expiration date), I need the jurisdiction. The phrase “Seebri patent” is used across multiple markets, and each has different patent filings and timelines.
Reply with:
1) the country (US, UK, EU, Canada, etc.), and
2) whether you mean Seebri Breezhaler (glycopyrronium) or another Seebri-branded product in that country,
and I’ll narrow it to the exact patent(s) and dates.